DK0696198T3 - Nyt polypeptid, der har inhiberende virkning mod faktor Xa - Google Patents

Nyt polypeptid, der har inhiberende virkning mod faktor Xa

Info

Publication number
DK0696198T3
DK0696198T3 DK94914087T DK94914087T DK0696198T3 DK 0696198 T3 DK0696198 T3 DK 0696198T3 DK 94914087 T DK94914087 T DK 94914087T DK 94914087 T DK94914087 T DK 94914087T DK 0696198 T3 DK0696198 T3 DK 0696198T3
Authority
DK
Denmark
Prior art keywords
polypeptide
novel polypeptide
inhibitory effect
effect against
against factor
Prior art date
Application number
DK94914087T
Other languages
English (en)
Inventor
Elisha P Zeelon
Moshe M Werber
Avigdor Levanon
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Application granted granted Critical
Publication of DK0696198T3 publication Critical patent/DK0696198T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK94914087T 1993-04-09 1994-04-08 Nyt polypeptid, der har inhiberende virkning mod faktor Xa DK0696198T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4580593A 1993-04-09 1993-04-09
PCT/US1994/003871 WO1994023735A1 (en) 1993-04-09 1994-04-08 Novel polypeptide having factor xa inhibitory activity

Publications (1)

Publication Number Publication Date
DK0696198T3 true DK0696198T3 (da) 2001-08-06

Family

ID=21939985

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94914087T DK0696198T3 (da) 1993-04-09 1994-04-08 Nyt polypeptid, der har inhiberende virkning mod faktor Xa

Country Status (14)

Country Link
EP (1) EP0696198B1 (da)
JP (1) JPH08511157A (da)
KR (1) KR960701649A (da)
AT (1) ATE198710T1 (da)
AU (1) AU682361B2 (da)
CA (1) CA2159218A1 (da)
DE (1) DE69426598T2 (da)
DK (1) DK0696198T3 (da)
ES (1) ES2155472T3 (da)
GR (1) GR3035722T3 (da)
IL (1) IL109259A0 (da)
NZ (1) NZ265507A (da)
PT (1) PT696198E (da)
WO (1) WO1994023735A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2008051178A2 (en) 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
DK3321359T3 (da) 2005-04-11 2021-03-08 Horizon Pharma Rheumatology Llc Variante former af uratoxidase og anvendelse deraf
CN102807973A (zh) 2005-04-11 2012-12-05 萨文特医药公司 尿酸氧化酶的变体形式及其用途
RU2535038C2 (ru) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови
US8685462B1 (en) 2012-09-17 2014-04-01 Biopep Solutions, Inc. Whole, leech saliva product and applications thereof
EP3538135A4 (en) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) * 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
DE58907266T2 (de) * 1988-06-11 1994-09-29 Ciba Geigy Ag Polypeptide mit einer die Koagulierung hemmenden Wirkung.
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
IL86856A0 (en) * 1988-06-24 1988-11-30 Yissum Res Dev Co Bovine xa factor and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
IL109259A0 (en) 1994-07-31
WO1994023735A1 (en) 1994-10-27
NZ265507A (en) 1998-09-24
JPH08511157A (ja) 1996-11-26
KR960701649A (ko) 1996-03-28
EP0696198B1 (en) 2001-01-17
HK1013315A1 (en) 1999-08-20
DE69426598T2 (de) 2001-08-09
PT696198E (pt) 2001-07-31
EP0696198A4 (en) 1999-01-27
EP0696198A1 (en) 1996-02-14
CA2159218A1 (en) 1994-10-27
GR3035722T3 (en) 2001-07-31
AU6629194A (en) 1994-11-08
AU682361B2 (en) 1997-10-02
ATE198710T1 (de) 2001-02-15
ES2155472T3 (es) 2001-05-16
DE69426598D1 (de) 2001-02-22

Similar Documents

Publication Publication Date Title
HU9203137D0 (en) New growth regulating proteines and epithelines rich in cysteine and their production
GR3035722T3 (en) Novel polypeptide having factor xa inhibitory activity
NO991796D0 (no) Fibroblastvekstfaktorhomologer
CA2108490A1 (en) Abrasive Material Based on Zirconium Corundum, a Process for Its Production and Its Use
DE69224237D1 (de) Bakteriocin von Lactococcus Lactis Subspezies Lactis
PL307258A1 (en) Peptides capable to block calcium canals with agelenopsis aperta
IL84852A0 (en) Molecular cloning and expression of human il-3
NZ506135A (en) Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis
TW281678B (da)
CA2093819A1 (en) Platelet adhesion inhibitor
WO1999009054A3 (en) Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders
DE69205154D1 (de) Verwendung von mindestens einem gereinigten peptid, welches durch kaseinhydrolyse hergestellt werden kann und opiataktivität hat, als aktiven bestandteil in der herstellung einer kosmetischen zusammensetzung.
DE69004794D1 (de) Verwendung eines Polypeptids mit Interleukin 2-Aktivität zur Herstellung einer zur Behandlung von einfachen Pleurageschwüren bestimmten pharmazeutischen Zusammensetzung.
GB2217331C (en) Oligopeptides and their use as analgesics
DE69429858D1 (de) Herstellung eines rekombinanten inhibitors des faktors xa des blutegels hirudo medicinalis
CA2375224A1 (en) Human antithrombin variants
Rawczynska-Englert et al. Staphylococcal endocarditis after valve replacement(9 years of experience).
UA7184C2 (uk) Контактний спосіб зниження артеріального тиску за методикою шпортюк м.і.
AU3217889A (en) Production of insulin-like growth factor binding protein
NZ337632A (en) Method for inhibiting human vascular IBF-like growth factor (VIGF) comprising a VIGF polypeptide or polypeptide having the cDNA contained in ATCC 75874